United States Biotechnology & Medical Research

Madrigal Pharmaceuticals Inc (MDGL)

Track

Over the past 90 days, Madrigal Pharmaceuticals Inc. saw 28 insider transactions, all of which were sales, totaling approximately $1.8 million in net value. Key executives, including CEO William Sibold and CMO David Soergel, conducted these disposals. These activities follow the company's May 2026 earnings report, where the firm outperformed EPS expectations by 66.7%.

Active selling signal · Moderate

Top insider sells (90, 60, 30, 7, 1d)

Top cluster sells (90d)

Top executive sells (90, 60, 30, 7, 1d)

Featured in screeners

Active selling signal · Moderate

Top insider sells

Top cluster sells

Top executive sells

Ticker: MDGL Exchange: NAS

• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings

Insider activity signal detected

18 activity signals detected for Madrigal Pharmaceuticals Inc

Upgrade for signal details

Upgrade to see score, net flow, insiders and context.

Upgrade to see full signal details →

Insider trades have triggered activity signals for Madrigal Pharmaceuticals Inc. Upgrade to see score, net flow, insiders and the full signal context.

Open in Activity Signals screener →

Top insiders

Company data & Insiders

Subscribe to get access to the company description and key fundamental data (market cap, shares outstanding, dividend yield, % of shares held by insiders and more)

Download results Settings

Trades

Sibold William John

President and CEO

10 sales — total 1,000,000 USD

Sale 20 Jul 2026

Value US$4,281,081.40 | Price 193.23 | Shares 13,578

Sale 20 Jul 2026

Value US$2,580,042.83 | Price 436.25 | Shares 10,069

Sale 20 Jul 2026

Value US$100,000.00 | Price 550.01 | Shares 1,000

Sale 20 Jul 2026

Value US$100,000.00 | Price 548.87 | Shares 1,000

Sale 20 Jul 2026

Value US$100,000.00 | Price 547.70 | Shares 1,000

Sale 20 Jul 2026

Value US$100,000.00 | Price 547.08 | Shares 1,000

Sale 20 Jul 2026

Value US$100,000.00 | Price 545.71 | Shares 1,000

Sale 20 Jul 2026

Value US$100,000.00 | Price 544.71 | Shares 1,000

Sale 20 Jul 2026

Value US$100,000.00 | Price 543.79 | Shares 1,000

Sale 20 Jul 2026

Value US$100,000.00 | Price 542.75 | Shares 1,000

William Sibold

Officer and Director

1 sale — total 100,000 USD

Proposed sale 20 Jul 2026

Value US$2,608,706.82 | Price 151.99 | Shares 60,650

Soergel David

Chief Medical Officer

1 sale — total 516,561 USD

Planned sale 1 Jun 2026

Value US$516,561.08 | Price 495.74 | Shares 1,042

DAVID SOERGEL

Officer

1 sale — total 518,155 USD

Proposed sale 1 Jun 2026

Value US$518,155.34 | Price 497.27 | Shares 1,042

Levy Richard S

12 sales — total 2,928,716 USD

Planned sale 22 May 2026

Value US$41,598.40 | Price 519.98 | Shares 80

Planned sale 22 May 2026

Value US$405,668.76 | Price 518.76 | Shares 782

Planned sale 22 May 2026

Value US$774,835.37 | Price 517.59 | Shares 1,497

Planned sale 22 May 2026

Value US$373,693.97 | Price 516.87 | Shares 723

Planned sale 22 May 2026

Value US$338,960.69 | Price 515.92 | Shares 657

Planned sale 22 May 2026

Value US$176,531.50 | Price 514.67 | Shares 343

Planned sale 22 May 2026

Value US$20,518.80 | Price 512.97 | Shares 40

Planned sale 22 May 2026

Value US$224,988.47 | Price 512.50 | Shares 439

Planned sale 22 May 2026

Value US$311,951.99 | Price 511.40 | Shares 610

Planned sale 22 May 2026

Value US$77,064.04 | Price 510.36 | Shares 151

Planned sale 22 May 2026

Value US$162,637.44 | Price 508.24 | Shares 320

Planned sale 22 May 2026

Value US$20,267.00 | Price 506.68 | Shares 40

RICHARD LEVY

Director

1 sale — total 2,918,218 USD

Proposed sale 22 May 2026

Value US$2,918,218.38 | Price 513.59 | Shares 5,682

David Soergel

Officer

1 sale — total 441,994 USD

Proposed sale 18 May 2026

Value US$441,994.36 | Price 523.69 | Shares 844

Soergel David

Chief Medical Officer

1 sale — total 435,420 USD

Sale 18 May 2026

Value US$435,419.60 | Price 515.90 | Shares 844

Dier Mardi

EVP and CFO

12 sales — total 853,993 USD

Planned sale 6 Mar 2026

Value US$17,506.00 | Price 437.65 | Shares 40

Planned sale 6 Mar 2026

Value US$34,935.20 | Price 436.69 | Shares 80

Planned sale 6 Mar 2026

Value US$34,825.20 | Price 435.32 | Shares 80

Planned sale 6 Mar 2026

Value US$69,472.00 | Price 434.20 | Shares 160

Planned sale 6 Mar 2026

Value US$50,176.48 | Price 432.56 | Shares 116

Planned sale 6 Mar 2026

Value US$51,708.40 | Price 430.90 | Shares 120

Planned sale 6 Mar 2026

Value US$17,183.20 | Price 429.58 | Shares 40

Planned sale 6 Mar 2026

Value US$68,639.20 | Price 429.00 | Shares 160

Planned sale 6 Mar 2026

Value US$34,227.60 | Price 427.85 | Shares 80

Planned sale 6 Mar 2026

Value US$179,282.80 | Price 426.86 | Shares 420

Planned sale 6 Mar 2026

Value US$17,003.20 | Price 425.08 | Shares 40

Sale 6 Mar 2026

Value US$279,033.24 | Price 431.94 | Shares 646

Mardi Dier

Officer

1 sale — total 283,814 USD

Proposed sale 6 Mar 2026

Value US$283,813.64 | Price 439.34 | Shares 646

Sibold William John

President and CEO

1 sale — total 718,316 USD

Sale 6 Mar 2026

Value US$718,316.22 | Price 431.94 | Shares 1,663

William Sibold

Officer and Director

1 sale — total 730,622 USD

Proposed sale 6 Mar 2026

Value US$730,622.42 | Price 439.34 | Shares 1,663

Kelley Shannon T

General Counsel

1 sale — total 155,498 USD

Sale 6 Mar 2026

Value US$155,498.40 | Price 431.94 | Shares 360

Shannon Kelley

Officer

1 sale — total 158,162 USD

Proposed sale 6 Mar 2026

Value US$158,162.40 | Price 439.34 | Shares 360

Huntsman Carole

Chief Commercial Officer

1 sale — total 180,983 USD

Sale 6 Mar 2026

Value US$180,982.86 | Price 431.94 | Shares 419

Carole Huntsman

Officer

1 sale — total 184,083 USD

Proposed sale 6 Mar 2026

Value US$184,083.46 | Price 439.34 | Shares 419

Taub Rebecca

1 sale — total 212,083 USD

Sale 6 Mar 2026

Value US$212,082.54 | Price 431.94 | Shares 491

Rebecca Taub

Director

1 sale — total 215,716 USD

Proposed sale 6 Mar 2026

Value US$215,715.94 | Price 439.34 | Shares 491

MARDI DIER

Officer

1 sale — total 586,958 USD

Proposed sale 6 Mar 2026

Value US$586,958.24 | Price 439.34 | Shares 1,336

Dier Mardi

EVP and CFO

1 sale — total 505,389 USD

Sale 2 Mar 2026

Value US$505,389.43 | Price 427.21 | Shares 1,183

Mardi Dier

Officer

1 sale — total 511,056 USD

Proposed sale 2 Mar 2026

Value US$511,056.00 | Price 432.00 | Shares 1,183

CAROLE A HUNTSMAN

Officer

1 sale — total 273,857 USD

Proposed sale 26 Jan 2026

Value US$273,856.50 | Price 480.45 | Shares 570

Carole Huntsman

Officer

1 sale — total 163,353 USD

Proposed sale 26 Jan 2026

Value US$163,353.00 | Price 480.45 | Shares 340

William Sibold

Officer and Director

1 sale — total 757,670 USD

Proposed sale 26 Jan 2026

Value US$757,669.65 | Price 480.45 | Shares 1,577

Rebecca Taub

Director

1 sale — total 310,851 USD

Proposed sale 26 Jan 2026

Value US$310,851.15 | Price 480.45 | Shares 647

Huntsman Carole

Chief Commercial Officer

2 sales — total 449,339 USD

Planned sale 26 Jan 2026

Value US$281,916.30 | Price 494.59 | Shares 570

Sale 26 Jan 2026

Value US$167,422.80 | Price 492.42 | Shares 340

Sibold William John

President and CEO

1 sale — total 776,546 USD

Sale 26 Jan 2026

Value US$776,546.34 | Price 492.42 | Shares 1,577

Taub Rebecca

1 sale — total 318,596 USD

Sale 26 Jan 2026

Value US$318,595.74 | Price 492.42 | Shares 647

SHANNON KELLEY

Officer

1 sale — total 215,221 USD

Proposed sale 20 Jan 2026

Value US$215,220.72 | Price 501.68 | Shares 429

Shannon Kelley

Officer

1 sale — total 131,942 USD

Proposed sale 20 Jan 2026

Value US$131,941.84 | Price 501.68 | Shares 263

Rebecca Taub

Director

1 sale — total 1,122,760 USD

Proposed sale 20 Jan 2026

Value US$1,122,759.84 | Price 501.68 | Shares 2,238

Kelley Shannon T

General Counsel

2 sales — total 344,173 USD

Planned sale 20 Jan 2026

Value US$215,100.60 | Price 501.40 | Shares 429

Sale 20 Jan 2026

Value US$129,072.51 | Price 490.77 | Shares 263

Taub Rebecca

1 sale — total 1,098,343 USD

Sale 20 Jan 2026

Value US$1,098,343.26 | Price 490.77 | Shares 2,238

FRIEDMAN PAUL A

9 sales — total 1,462,067 USD

Planned sale 9 Jan 2026

Value US$21,831.60 | Price 545.79 | Shares 40

Planned sale 9 Jan 2026

Value US$324,214.80 | Price 540.36 | Shares 600

Planned sale 9 Jan 2026

Value US$258,831.22 | Price 539.23 | Shares 480

Planned sale 9 Jan 2026

Value US$43,027.60 | Price 537.85 | Shares 80

Planned sale 9 Jan 2026

Value US$261,459.00 | Price 536.88 | Shares 487

Planned sale 9 Jan 2026

Value US$253,537.74 | Price 536.02 | Shares 473

Planned sale 9 Jan 2026

Value US$79,222.71 | Price 535.29 | Shares 148

Planned sale 9 Jan 2026

Value US$177,342.38 | Price 534.16 | Shares 332

Planned sale 9 Jan 2026

Value US$42,600.00 | Price 532.50 | Shares 80

Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other

Notification date	Transaction date	B/S Transaction type	Insider and/or position	Nb. shares Price Value	Number of shares	Price	Value
2026-07-20	2026-07-20	S Sale	2.6 Sibold William John President and CEO Executive Director	13,578 -10.5% 193.23 US$4,281,081	13,578 -10.5%	193.23	US$4,281,081
2026-07-20	2026-07-20	S Sale	2.6 Sibold William John President and CEO Executive Director	10,069 -28.4% 436.25 US$2,580,043	10,069 -28.4%	436.25	US$2,580,043
2026-07-20	2026-07-20	S Sale	2.6 Sibold William John President and CEO Executive Director	22,601 +14.3% 191.86 US$503,650	22,601 +14.3%	191.86	US$503,650
2026-07-20	2026-07-20	S Sale	2.6 Sibold William John President and CEO Executive Director	1,000 -0.0% 548.87 US$100,000	1,000 -0.0%	548.87	US$100,000
2026-07-20	2026-07-20	S Sale	2.6 Sibold William John President and CEO Executive Director	1,000 -0.3% 547.70 US$100,000	1,000 -0.3%	547.70	US$100,000
2026-07-20	2026-07-20	S Sale	2.6 Sibold William John President and CEO Executive Director	1,000 -0.1% 547.08 US$100,000	1,000 -0.1%	547.08	US$100,000
2026-07-20	2026-07-20	S Sale	2.6 Sibold William John President and CEO Executive Director	1,000 -0.1% 545.71 US$100,000	1,000 -0.1%	545.71	US$100,000
2026-07-20	2026-07-20	S Sale	2.6 Sibold William John President and CEO Executive Director	1,000 -0.3% 544.71 US$100,000	1,000 -0.3%	544.71	US$100,000
2026-07-20	2026-07-20	S Sale	2.6 Sibold William John President and CEO Executive Director	1,000 -0.1% 543.79 US$100,000	1,000 -0.1%	543.79	US$100,000
2026-07-20	2026-07-20	S Sale	2.6 Sibold William John President and CEO Executive Director	1,000 -0.1% 542.75 US$100,000	1,000 -0.1%	542.75	US$100,000
2026-07-20	2026-07-20	PrS Proposed sale	2.6 William Sibold Officer and Director Executive Director	1,000 553.48 US$100,000	1,000	553.48	US$100,000
2026-06-01	2026-06-01	PlS Planned sale	Soergel David Chief Medical Officer Officer	1,042 -9.4% 495.74 US$516,561	1,042 -9.4%	495.74	US$516,561
2026-06-01	2026-06-01	PrS Proposed sale	DAVID SOERGEL Officer Officer	1,042 497.27 US$518,155	1,042	497.27	US$518,155
2026-05-22	2026-05-22	PlS Planned sale	3.5 Levy Richard S Non-Executive Director	80 -0.4% 519.98 US$41,598	80 -0.4%	519.98	US$41,598
2026-05-22	2026-05-22	PlS Planned sale	3.5 Levy Richard S Non-Executive Director	782 -3.4% 518.76 US$405,669	782 -3.4%	518.76	US$405,669
2026-05-22	2026-05-22	PlS Planned sale	3.5 Levy Richard S Non-Executive Director	1,497 -6.1% 517.59 US$774,835	1,497 -6.1%	517.59	US$774,835
2026-05-22	2026-05-22	PlS Planned sale	3.5 Levy Richard S Non-Executive Director	723 -2.9% 516.87 US$373,694	723 -2.9%	516.87	US$373,694
2026-05-22	2026-05-22	PlS Planned sale	3.5 Levy Richard S Non-Executive Director	657 -2.6% 515.92 US$338,961	657 -2.6%	515.92	US$338,961
2026-05-22	2026-05-22	PlS Planned sale	3.5 Levy Richard S Non-Executive Director	343 -1.3% 514.67 US$176,532	343 -1.3%	514.67	US$176,532
2026-05-22	2026-05-22	PlS Planned sale	3.5 Levy Richard S Non-Executive Director	40 -0.2% 512.97 US$20,519	40 -0.2%	512.97	US$20,519
2026-05-22	2026-05-22	PlS Planned sale	3.5 Levy Richard S Non-Executive Director	439 -1.7% 512.50 US$224,988	439 -1.7%	512.50	US$224,988
2026-05-22	2026-05-22	PlS Planned sale	3.5 Levy Richard S Non-Executive Director	610 -2.2% 511.40 US$311,952	610 -2.2%	511.40	US$311,952
2026-05-22	2026-05-22	PlS Planned sale	3.5 Levy Richard S Non-Executive Director	151 -0.6% 510.36 US$77,064	151 -0.6%	510.36	US$77,064
2026-05-22	2026-05-22	PlS Planned sale	3.5 Levy Richard S Non-Executive Director	320 -1.2% 508.24 US$162,637	320 -1.2%	508.24	US$162,637
2026-05-22	2026-05-22	PlS Planned sale	3.5 Levy Richard S Non-Executive Director	40 -0.1% 506.68 US$20,267	40 -0.1%	506.68	US$20,267
2026-05-22	2026-05-22	PrS Proposed sale	3.5 RICHARD LEVY Director Non-Executive Director	5,682 513.59 US$2,918,218	5,682	513.59	US$2,918,218
2026-05-18	2026-05-18	PrS Proposed sale	David Soergel Officer Officer	844 523.69 US$441,994	844	523.69	US$441,994
2026-05-18	2026-05-18	S Sale	Soergel David Chief Medical Officer Officer	844 -7.1% 515.90 US$435,420	844 -7.1%	515.90	US$435,420
2026-03-06	2026-03-06	PlS Planned sale	2.4 Dier Mardi EVP and CFO Officer	40 -0.3% 437.65 US$17,506	40 -0.3%	437.65	US$17,506
2026-03-06	2026-03-06	PlS Planned sale	2.4 Dier Mardi EVP and CFO Officer	80 -0.6% 436.69 US$34,935	80 -0.6%	436.69	US$34,935
2026-03-06	2026-03-06	PlS Planned sale	2.4 Dier Mardi EVP and CFO Officer	80 -0.6% 435.32 US$34,825	80 -0.6%	435.32	US$34,825
2026-03-06	2026-03-06	PlS Planned sale	2.4 Dier Mardi EVP and CFO Officer	160 -1.2% 434.20 US$69,472	160 -1.2%	434.20	US$69,472
2026-03-06	2026-03-06	PlS Planned sale	2.4 Dier Mardi EVP and CFO Officer	116 -0.9% 432.56 US$50,176	116 -0.9%	432.56	US$50,176
2026-03-06	2026-03-06	PlS Planned sale	2.4 Dier Mardi EVP and CFO Officer	120 -0.9% 430.90 US$51,708	120 -0.9%	430.90	US$51,708
2026-03-06	2026-03-06	PlS Planned sale	2.4 Dier Mardi EVP and CFO Officer	40 -0.3% 429.58 US$17,183	40 -0.3%	429.58	US$17,183
2026-03-06	2026-03-06	PlS Planned sale	2.4 Dier Mardi EVP and CFO Officer	160 -1.2% 429.00 US$68,639	160 -1.2%	429.00	US$68,639
2026-03-06	2026-03-06	PlS Planned sale	2.4 Dier Mardi EVP and CFO Officer	80 -0.6% 427.85 US$34,228	80 -0.6%	427.85	US$34,228
2026-03-06	2026-03-06	PlS Planned sale	2.4 Dier Mardi EVP and CFO Officer	420 -3.0% 426.86 US$179,283	420 -3.0%	426.86	US$179,283
2026-03-06	2026-03-06	PlS Planned sale	2.4 Dier Mardi EVP and CFO Officer	40 -0.3% 425.08 US$17,003	40 -0.3%	425.08	US$17,003
2026-03-06	2026-03-06	S Sale	2.4 Dier Mardi EVP and CFO Officer	646 -4.5% 431.94 US$279,033	646 -4.5%	431.94	US$279,033
2026-03-06	2026-03-06	PrS Proposed sale	2.4 Mardi Dier Officer Officer	646 439.34 US$283,814	646	439.34	US$283,814
2026-03-06	2026-03-06	S Sale	2.6 Sibold William John President and CEO Executive Director	1,663 -1.0% 431.94 US$718,316	1,663 -1.0%	431.94	US$718,316
2026-03-06	2026-03-06	PrS Proposed sale	2.6 William Sibold Officer and Director Executive Director	1,663 439.34 US$730,622	1,663	439.34	US$730,622
2026-03-06	2026-03-06	S Sale	1.6 Kelley Shannon T General Counsel Officer	360 -2.9% 431.94 US$155,498	360 -2.9%	431.94	US$155,498
2026-03-06	2026-03-06	PrS Proposed sale	1.6 Shannon Kelley Officer Officer	360 439.34 US$158,162	360	439.34	US$158,162
2026-03-06	2026-03-06	S Sale	2.8 Huntsman Carole Chief Commercial Officer Officer	419 -3.2% 431.94 US$180,983	419 -3.2%	431.94	US$180,983
2026-03-06	2026-03-06	PrS Proposed sale	2.8 Carole Huntsman Officer Officer	419 439.34 US$184,083	419	439.34	US$184,083
2026-03-06	2026-03-06	S Sale	2.4 Taub Rebecca Non-Executive Director	491 -0.1% 431.94 US$212,083	491 -0.1%	431.94	US$212,083
2026-03-06	2026-03-06	PrS Proposed sale	2.4 Rebecca Taub Director Non-Executive Director	491 439.34 US$215,716	491	439.34	US$215,716
2026-03-06	2026-03-06	PrS Proposed sale	2.4 MARDI DIER Officer Officer	1,336 439.34 US$586,958	1,336	439.34	US$586,958
2026-03-02	2026-03-02	S Sale	2.4 Dier Mardi EVP and CFO Officer	1,183 -11.3% 427.21 US$505,389	1,183 -11.3%	427.21	US$505,389
2026-03-02	2026-03-02	PrS Proposed sale	2.4 Mardi Dier Officer Officer	1,183 432.00 US$511,056	1,183	432.00	US$511,056
2026-01-26	2026-01-26	PrS Proposed sale	2.8 CAROLE A HUNTSMAN Officer Officer	570 480.45 US$273,856	570	480.45	US$273,856
2026-01-26	2026-01-26	PrS Proposed sale	2.8 Carole Huntsman Officer Officer	340 480.45 US$163,353	340	480.45	US$163,353
2026-01-26	2026-01-26	PrS Proposed sale	2.6 William Sibold Officer and Director Executive Director	1,577 480.45 US$757,670	1,577	480.45	US$757,670
2026-01-26	2026-01-26	PrS Proposed sale	2.4 Rebecca Taub Director Non-Executive Director	647 480.45 US$310,851	647	480.45	US$310,851
2026-01-26	2026-01-26	PlS Planned sale	2.8 Huntsman Carole Chief Commercial Officer Officer	570 -5.9% 494.59 US$281,916	570 -5.9%	494.59	US$281,916
2026-01-26	2026-01-26	S Sale	2.8 Huntsman Carole Chief Commercial Officer Officer	340 -3.4% 492.42 US$167,423	340 -3.4%	492.42	US$167,423
2026-01-26	2026-01-26	S Sale	2.6 Sibold William John President and CEO Executive Director	1,577 -1.1% 492.42 US$776,546	1,577 -1.1%	492.42	US$776,546
2026-01-26	2026-01-26	S Sale	2.4 Taub Rebecca Non-Executive Director	647 -0.1% 492.42 US$318,596	647 -0.1%	492.42	US$318,596
2026-01-20	2026-01-20	PrS Proposed sale	1.6 SHANNON KELLEY Officer Officer	429 501.68 US$215,221	429	501.68	US$215,221
2026-01-20	2026-01-20	PrS Proposed sale	1.6 Shannon Kelley Officer Officer	263 501.68 US$131,942	263	501.68	US$131,942
2026-01-20	2026-01-20	PrS Proposed sale	2.4 Rebecca Taub Director Non-Executive Director	2,238 501.68 US$1,122,760	2,238	501.68	US$1,122,760
2026-01-20	2026-01-20	PlS Planned sale	1.6 Kelley Shannon T General Counsel Officer	429 -4.8% 501.40 US$215,101	429 -4.8%	501.40	US$215,101
2026-01-20	2026-01-20	S Sale	1.6 Kelley Shannon T General Counsel Officer	263 -2.9% 490.77 US$129,073	263 -2.9%	490.77	US$129,073
2026-01-20	2026-01-20	S Sale	2.4 Taub Rebecca Non-Executive Director	2,238 -0.5% 490.77 US$1,098,343	2,238 -0.5%	490.77	US$1,098,343
2026-01-13	2026-01-09	PlS Planned sale	2.5 FRIEDMAN PAUL A Non-Executive Director	40 -0.0% 545.79 US$21,832	40 -0.0%	545.79	US$21,832
2026-01-13	2026-01-09	PlS Planned sale	2.5 FRIEDMAN PAUL A Non-Executive Director	600 -0.3% 540.36 US$324,215	600 -0.3%	540.36	US$324,215
2026-01-13	2026-01-09	PlS Planned sale	2.5 FRIEDMAN PAUL A Non-Executive Director	480 -0.3% 539.23 US$258,831	480 -0.3%	539.23	US$258,831
2026-01-13	2026-01-09	PlS Planned sale	2.5 FRIEDMAN PAUL A Non-Executive Director	80 -0.0% 537.85 US$43,028	80 -0.0%	537.85	US$43,028
2026-01-13	2026-01-09	PlS Planned sale	2.5 FRIEDMAN PAUL A Non-Executive Director	487 -0.3% 536.88 US$261,459	487 -0.3%	536.88	US$261,459
2026-01-13	2026-01-09	PlS Planned sale	2.5 FRIEDMAN PAUL A Non-Executive Director	473 -0.2% 536.02 US$253,538	473 -0.2%	536.02	US$253,538
2026-01-13	2026-01-09	PlS Planned sale	2.5 FRIEDMAN PAUL A Non-Executive Director	148 -0.1% 535.29 US$79,223	148 -0.1%	535.29	US$79,223
2026-01-13	2026-01-09	PlS Planned sale	2.5 FRIEDMAN PAUL A Non-Executive Director	332 -0.2% 534.16 US$177,342	332 -0.2%	534.16	US$177,342
2026-01-13	2026-01-09	PlS Planned sale	2.5 FRIEDMAN PAUL A Non-Executive Director	80 -0.0% 532.50 US$42,600	80 -0.0%	532.50	US$42,600

Explore more

More insider trading research around Madrigal Pharmaceuticals Inc

More insider trades in United States

Similar Healthcare companies with insider activity

More Pharmaceuticals & Medical Research companies with insider activity

More Biotechnology & Medical Research companies with insider activity

Insider trading in North America

Madrigal Pharmaceuticals Inc (MDGL)

Track

Featured in screeners

Upgrade for signal details

Transactions

Insider

Sort by

Trades

Explore more